CSL possible pull back to low $200's, page-39

Agreed the SP has remained [$270 - $330] rangebound for a period of time but when the companies pipeline is studied you will find in that same period significant advances have been made.

Once these therapies [one or two underway carry blockbuster potential] hit a Phase III trial, pass the futility tests, and come before the FDA for approval; the SP will appreciate considerably. The low $300's will seem like a golden opportunity missed.

Even the bread and butter stuff like flu vaccines are now being seen as of benefit to folks, and there are a lot of them out there, who always remained skeptical of the science behind innoculation...and you can always count on the Australian dollar to tank at some point.